The Perceived Value of Liquid Biopsy: Results From a Canadian Validation Study of Circulating Tumor DNA T790M Testing-Patient's Willingness-to-Pay: A Brief Report.

Autor:	Chen KH; Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Barnes TA; Medical Oncology, North Shore Private Hospital, St Leonard's, Australia., Laskin J; Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada., Cheema P; Medical Oncology, William Osler Health System, Brampton, Ontario, Canada., Liu G; Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Iqbal M; Medical Oncology, Allan Blair Cancer Centre, Regina, Saskatoon, Canada., Rothenstein J; Medical Oncology, Lakeridge Health, Oshawa, Ontario, Canada., Burkes R; Medical Oncology, Mount Sinai Hospital, Toronto, Ontario, Canada., Tsao MS; Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Laboratory Medicine and Pathology, University Health Network, Toronto, Ontario, Canada., Leighl NB; Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Jazyk:	angličtina
Zdroj:	JTO clinical and research reports [JTO Clin Res Rep] 2023 Nov 28; Vol. 5 (1), pp. 100615. Date of Electronic Publication: 2023 Nov 28 (Print Publication: 2024).
DOI:	10.1016/j.jtocrr.2023.100615
Abstrakt:	Introduction: Liquid biopsy is recommended to diagnose molecular resistance to targeted therapy in patients with lung cancer. Nevertheless, not all jurisdictions provide funding and patient access. We report patients' perceived value of liquid biopsy in targeted therapy resistance. Methods: Canadian patients participating in a national EGFR T790M liquid biopsy validation study completed structured interviews measuring perceived value and willingness-to-pay for plasma circulating tumor DNA testing as an alternative to tumor biopsy using open-ended and iterative bidding approaches. Results: A total of 60 patients with advanced lung cancer participated with a median age of 64 years (range: 31-87 y); 69% were Asian and 45% female. All had received prior EGFR tyrosine kinase inhibitor; 17% also received chemotherapy. All patients preferred to have plasma testing over repeat tumor biopsy. In the context of the Canadian publicly funded system, patients estimated that a median of 300 (interquartile range: 150-800) Canadian dollars was a reasonable price to pay for liquid biopsy. Patients were personally willing to pay a median 100 (interquartile range: 33-350) Canadian dollars. Conclusions: In a system that covers the cost of standard diagnostic tests, patients with lung cancer indicated high willingness-to-pay out-of-pocket for liquid biopsy in the setting of acquired targeted therapy resistance. Patients have high perceived value of plasma genotyping and prefer it to repeat tumor biopsy. (© 2024 by the International Association for the Study of Lung Cancer.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu